The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Indivumed and CELLphenomics form partnership for improved patient care in EU-funded project

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Indivumed GmbH and CELLphenomics GmbH have formed a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.
Clinical Roundup

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk.  By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account